{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:32Z","timestamp":1707524732310},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.7759\/cureus.28699","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T17:03:59Z","timestamp":1662138239000},"source":"Crossref","is-referenced-by-count":0,"title":["The Decalcification of Cervicothoracic Spinal Metastasis of Breast Cancer Due to Discontinuation of Denosumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Masaki","family":"Tatsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousei","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak C","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE, et al.. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017, 35:3978-86. 10.1200\/JCO.2017.75.4614","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman R","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, et al.. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020, 31:1650-63. 10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx RE","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003, 61:1115-7. 10.1016\/s0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2013.90","article-title":"The potential for functional recovery of upper extremity function following cervical spinal cord injury without major bone injury","volume":"51","author":"Hayashi T","year":"2013","unstructured":"Hayashi T, Kawano O, Sakai H, et al.. The potential for functional recovery of upper extremity function following cervical spinal cord injury without major bone injury. Spinal Cord. 2013, 51:819-22. 10.1038\/sc.2013.90","journal-title":"Spinal Cord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero SL","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014, 72:1938-56. 10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.263","article-title":"Diagnosis and surgical management of breast cancer metastatic to the spine","volume":"5","author":"Ju DG","year":"2014","unstructured":"Ju DG, Yurter A, Gokaslan ZL, Sciubba DM. Diagnosis and surgical management of breast cancer metastatic to the spine. World J Clin Oncol. 2014, 5:263-71. 10.5306\/wjco.v5.i3.263","journal-title":"World J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi K","year":"2021","unstructured":"Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: a systematic review. Bone Rep. 2021, 15:101148. 10.1016\/j.bonr.2021.101148","journal-title":"Bone Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux B","year":"2022","unstructured":"Cadieux B, Coleman R, Jafarinasabian P, et al.. Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol. 2022, 33:100416. 10.1016\/j.jbo.2022.100416","journal-title":"J Bone Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan A","year":"2019","unstructured":"Tyan A, Patel SP, Block S, Hughes T, McCowen KC. Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale. Mayo Clin Proc Innov Qual Outcomes. 2019, 3:235-7. 10.1016\/j.mayocpiqo.2019.02.003","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi M","year":"2019","unstructured":"Takahashi M, Ozaki Y, Kizawa R, et al.. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019, 19:980. 10.1186\/s12885-019-6236-6","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/113061-the-decalcification-of-cervicothoracic-spinal-metastasis-of-breast-cancer-due-to-discontinuation-of-denosumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:30Z","timestamp":1707507630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/113061-the-decalcification-of-cervicothoracic-spinal-metastasis-of-breast-cancer-due-to-discontinuation-of-denosumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.28699","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}